Image de couverture de livre

Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Beatrice Casadei, Gabriele Conti, Monica Barone, Silvia Turroni, Serafina Guadagnuolo, Alessandro Broccoli, Patrizia Brigidi, Lisa Argnani, Pier Luigi Zinzani
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Hematological Oncology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario
par: Antonio Pinto, et autres
Publié: (2024)

409 | EARLY IDENTIFICATION OF CAR T‐CELL THERAPY NON‐RESPONDERS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA USING FDG‐PET QUANTITATIVE PARAMETERS
par: C. Pellegrini, et autres
Publié: (2025)

Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus‐based position paper from an ad hoc expert panel
par: Francesca Romana Mauro, et autres
Publié: (2024)

A Real‐Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B ‐Cell Lymphoma
par: Gabriele Gugliotta, et autres
Publié: (2026)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
par: Pier Luigi Zinzani, et autres
Publié: (2025)

A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
par: Monia Marchetti, et autres
Publié: (2025)

349 | PEMBROLIZUMAB OR NIVOLUMAB COMBINED WITH BRENTUXIMAB‐VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B‐CELL LYMPHOMA: AN ITALIAN REAL‐LIFE STUDY
par: A. Broccoli, et autres
Publié: (2025)

Drug‐induced autoimmune hemolytic anemias related to immune checkpoint inhibitors, therapeutic management, and outcome
par: Marion Plaçais, et autres
Publié: (2024)

Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials
par: Mohammed Zuber, et autres
Publié: (2024)

855 | A PHASE 3 RANDOMIZED TRIAL: DUVELISIB VERSUS INVESTIGATOR CHOICE (GEMCITABINE OR BENDAMUSTINE) IN RELAPSED/REFRACTORY NODAL T‐CELL LYMPHOMA WITH T‐FOLLICULAR HELPER PHENOTYPE
par: K. Cwynarski, et autres
Publié: (2025)

Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients
par: Kaitlin Annunzio, et autres
Publié: (2024)

Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real‐world cohort analysis
par: Adam S. Kittai, et autres
Publié: (2024)

Outcomes after treating advanced mantle cell lymphoma in a low‐income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation
par: José Carlos Jaime‐Pérez, et autres
Publié: (2024)

Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement
par: Elisabetta M. Abenavoli, et autres
Publié: (2024)

847 | PALT TRIAL: FIRST IN CLASS GLYCO‐HUMANIZED POLYCLONAL ANTIBODY DIRECTED AGAINST TUMORAL T CELLS, IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T CELLS LYMPHOMA
par: G. Damaj, et autres
Publié: (2025)

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
par: Giacomo Loseto, et autres
Publié: (2025)

Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group
par: Evgenia Verrou, et autres
Publié: (2024)

850 | GOLSEEK‐2: A PHASE 2 RANDOMIZED, OPEN‐LABEL STUDY OF GOLCADOMIDE IN COMBINATION WITH RITUXIMAB IN PARTICIPANTS WITH NEWLY DIAGNOSED ADVANCED‐STAGE FOLLICULAR LYMPHOMA
par: P. Luigi Zinzani, et autres
Publié: (2025)

Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4‐positive peripheral T‐cell lymphoma and relapsed or refractory cutaneous T‐cell lymphoma: A post‐marketing surveillance in Japan
par: Kenji Ishitsuka, et autres
Publié: (2024)

Characterizing second line and beyond therapies for primary central nervous system lymphomas
par: Brian Primeaux, et autres
Publié: (2024)

Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203
par: Takashi Watanabe, et autres
Publié: (2024)

PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay: A highly sensitive method for detection of MYD88 L265P mutation
par: Marcello Viscovo, et autres
Publié: (2024)

46 | EFFICACY OF RITUXIMAB‐BENDAMUSTINE WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH UNTREATED, HIGH‐RISK MANTLE CELL LYMPHOMA: AN ANALYSIS OF THE PHASE 3 ECHO TRIAL
par: M. Dreyling, et autres
Publié: (2025)

833 | PRO‐MIND: PROSPECTIVE REAL‐WORLD STUDY OF TAFASITAMAB PLUS LENALIDOMIDE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN ITALY—AN ONGOING TRIAL
par: P. L. Zinzani, et autres
Publié: (2025)

High‐grade B‐cell lymphoma not otherwise specified, with diffuse large B‐cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics
par: Waseem Lone, et autres
Publié: (2024)

Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management
par: Stephen M. Ansell
Publié: (2024)

Management of post‐autologous transplant relapse in patients with T‐cell lymphomas
par: Olivier Veilleux, et autres
Publié: (2024)

Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management
par: Andres Ramirez‐Gamero, et autres
Publié: (2024)

New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model
par: Maria Anele Romeo, et autres
Publié: (2024)

Antibody targeting of surface P‐selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition
par: João L. Pereira, et autres
Publié: (2024)

256 | NEMTABRUTINIB IN RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: UPDATED RESULTS FROM COHORT F OF THE PHASE 2 BELLWAVE‐003 STUDY
par: A. Tucci, et autres
Publié: (2025)

136 | MINIMAL RESIDUAL DISEASE WITH BENDAMUSTINE‐RITUXIMAB WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE ECHO TRIAL
par: P. L. Zinzani, et autres
Publié: (2025)

Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus‐associated mantle cell lymphoma
par: Jiangfang Feng, et autres
Publié: (2024)

Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib
par: Alessandro Broccoli, et autres
Publié: (2025)

350 | PATIENTS WITH RELAPSED/REFRACTORY PMBCL HAVE BETTER SURVIVAL WHEN THE SALVAGE STRATEGY INCLUDES CAR T‐CELLS: AN ANALYSIS OF THE REPRIME‐FIL AND THE CART‐SIE STUDIES
par: A. Guidetti, et autres
Publié: (2025)

Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes
par: Xiaohui Wang, et autres
Publié: (2024)

351 | FINAL SAFETY ANALYSIS IN PARTICIPANTS WITH HEMATOLOGIC MALIGNANCIES WHO RECEIVED ALLOGENEIC STEM CELL TRANSPLANT AFTER PEMBROLIZUMAB THERAPY
par: J. Kuruvilla, et autres
Publié: (2025)

The role of baseline 2‐[ 18 F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis
par: Domenico Albano, et autres
Publié: (2024)

441 | GOLCADOMIDE, A CEREBLON E3 LIGASE MODULATOR (CELMoD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED PHASE 1/2 RESULTS
par: R. Cordoba, et autres
Publié: (2025)

Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD
par: Carmen Martínez, et autres
Publié: (2024)